May 27,2021

The Frequency of Intermittently Scanned Glucose and Diurnal Variation of Glycemic Metrics

The relation between the frequency of intermittently scanned continuous glucose monitoring (isCGM) and diurnal variation of time in range (TIR) and time below range (TBR) is unknown.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 27,2021

Wellthy Therapeutics demonstrates real world outcomes to manage chronic conditions (inc. diabetes) with Wellthy CARE DTx platform

Wellthy Therapeutics, a leading digital therapeutics (DTx) company operating in Europe and Asia, conducted a 16-week real world study, to test the real-world effectiveness, efficacy and remote patient monitoring and management capabilities of its Wellthy CARE DTx platform

PRODUCT

#dtx

View Analyst & Ambassador Comments
Go to original news
May 28,2021

A Video Game for Brazilian T1D Children about Knowledge of Disease and Self-care: A Methodological Study

Video games are interactive technologies able to support children in health promotion, behavior changes, and chronic disease self-management. The use of health behavior change determinants in video game design can increase its effectiveness. This study describes the process of designing a video game for Brazilian children with T1D clarifying the use of health behavior change determinants that may influence self-management behaviors.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 30,2021

A Conditional Generative Adversarial Network for Synthesis of Continuous Glucose Monitoring Signals

This report describes how a Conditional Generative Adversarial Network (CGAN) was used to synthesize realistic continuous glucose monitoring systems (CGM) from healthy individuals and individuals with type 1 diabetes over a range of different HbA1c levels.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
May 31,2021

Brighter Publishes the Annual Report for the Financial Year 2020

Brighter AB [publ], today has published the company’s Annual Report for Fiscal Year 2020. The full report is available on the company website https://brighter.se.

View Analyst & Ambassador Comments
Go to original news
Jun 12,2021

Wellthy Therapeutics demonstrates real world outcomes to manage chronic conditions

Wellthy Therapeutics, a leading digital therapeutics (DTx) company operating in Europe and Asia, recently conducted a 16-week real-world study, to test the real-world effectiveness, efficacy and remote patient monitoring and management capabilities of its Wellthy CARE ™ DTx platform. The platform consists of a clinical and behavioural intelligence engine, delivering care through a mobile app, paramedical dashboards, HCP dashboards and enterprise analytics. In this study, a clinically validated Type 2 Diabetes Digital Therapy was delivered through the Wellthy CARE DTx platform, to evaluate glycemic control in Type 2 Diabetes Mellitus (T2DM) patients of South Asian origin. The findings were published in the Journal of Medical Internet Research (JMIR) as a full text publication.

PRODUCT

#mobile app

#dtx

#rpm

View Analyst & Ambassador Comments
Go to original news
Jun 23,2021

Digital Leaders Impact Awards Winner of 2021 In The HealthTech Category

We are proud to announce that MyWay Digital Health is the winner in the HealthTech category of the 2021 Digital Leaders Impact Awards. The 5th Annual Digital Leaders Impact Awards highlighted the latest champions of Tech for Good across the UK.

View Analyst & Ambassador Comments
Go to original news
Jun 01,2021

ABBOTT ISSUES UPDATED 2021 OUTLOOK

Abbott today announced an update to its financial outlook for the full-year 2021. The updated guidance is due to significantly lower recent and projected COVID-19 diagnostic testing demand. This has been driven by several factors, including significant reductions in cases in the U.S. and other major developed countries, accelerated rollout of COVID-19 vaccines globally and, most recently, U.S. health authority guidance on testing for fully vaccinated individuals.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 01,2021

Nemaura Medical to Present at the LD Micro Virtual Invitational Conference on June 9, 2021

Nemaura Medical, Inc. today announced that Chief Executive Officer Faz Chowdhury, Ph.D. will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10, 2021.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 01,2021

Non-invasive wearables for remote monitoring of HbA1c and glucose variability: proof of concept

Introduction Diabetes prevalence continues to grow and there remains a significant diagnostic gap in one-third of the US population that has pre-diabetes. Innovative, practical strategies to improve monitoring of glycemic health are desperately needed. In this proof-of-concept study, we explore the relationship between non-invasive wearables and glycemic metrics and demonstrate the feasibility of using non-invasive wearables to estimate glycemic metrics, including hemoglobin A1c (HbA1c) and glucose variability metrics.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES